BNZI Surges Ahead: AI Marketing Solutions Fuel Record Revenue, Expanded Customer Base, and Strategic Acquisitions.
Amid a tsunami of AI headlines, Banzai International, Inc. (NASDAQ: BNZI) is rapidly emerging as a leader in AI-powered marketing technology, offering solutions that increase customer value out of the box and drive measurable business growth.
The company achieved $2.8 million in Q3 2025 revenue, a 163% increase from last year, and gross profit of $2.3 million, up 213%, while gross margins climbed to 81.7%, reflecting strong operational leverage.
Its annual recurring revenue hit $11 million, supported by more than 140,000 customers, including major corporations like Globe Life, Nextiva, and Sprinklr. These results highlight BNZI’s ability to scale efficiently while delivering high-value solutions in acquisition, engagement, and analytics.
BNZI’s strategic focus includes expanding AI capabilities through acquisitions like Superblocks, strengthening its leadership team, and executing disciplined financial management with debt reduction and improved stockholders’ equity.
Flagship platforms such as Demio, OpenReel, CreateStudio, Reach, Boost, and Curate showcase the company’s ability to drive customer engagement, simplify marketing operations, and generate measurable ROI.
With AI-driven innovation, robust growth metrics, and a growing footprint in the marketing tech space, BNZI is well-positioned to capture market share and deliver long-term value to both customers and investors.
2 Small-Cap Biotechs That Could Reward Patient Investors
Authored by Chris Markoch. Posted: 12/12/2025.
Article Highlights
- Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you're considering the small-cap biotech sector, however, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics.
They typically have negative earnings (not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic.
Best $19 you'll spend this year. (Ad)
A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his "One Ticker" approach works — and how readers can access the full service for a year at a steep discount.
Watch the brief demo hereEven when a product advances through trials, profitability can still be years away. Only after reaching that stage do companies usually attract analyst coverage and institutional investment.
That said, investing early in one of these medical stocks and seeing it succeed can feel like winning the lottery. Investors can post 3x, 5x or even 10x returns in an instant — though many companies never pan out. For that reason, many investors who buy penny stocks divide a lump sum across multiple biotech names. If it's a numbers game, diversification can be an effective strategy.
With that in mind, here are two small-cap biotech stocks that carry significant risks but also offer potential for outsized returns.
Mainz Biomed: Early Cancer Detection With High Upside Potential
Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in the space, Mainz Biomed has a commercially available product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe.
On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's pioneers in digital health. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is significant.
Mainz Biomed is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. That program, however, is still years away from potential commercial approval.
But risks remain substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue is still minimal.
That shortfall is reflected in the company's regulatory filings: it included "Going Concern" language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that capital strategy helps keep the MYNZ share price above $1 and avoids a delisting notice.
The company needs to generate meaningful revenue to change the picture. If it succeeds, even a modest investment could deliver a sizable return.
NanoViricides: High-Risk Antiviral Play With Breakthrough Potential
NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that pursues a potentially disruptive antiviral approach — but it also carries the financial risks that speculative investors must weigh carefully.
The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform.
These candidates mimic human cell surfaces to lure and bind viruses, neutralizing them before they can infect real cells. If this approach is validated in human trials, it could represent a fundamentally new method for treating infectious diseases.
NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting strong antiviral activity.
Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance its programs. Recent filings indicate limited cash on hand, so investors should be prepared for the possibility of future dilution.
Still, if even one candidate advances into clinical development successfully, the valuation upside could be meaningful. For investors with patience and a high tolerance for risk, NNVC stock represents a true moonshot in the antiviral space.
This email content is a paid advertisement for Huge Alerts, a third-party advertiser of Earnings360 and MarketBeat.
This message is a paid advertisement for Banzai International, Inc. (NASDAQ: BNZI) from Huge Alerts and Sideways Frequency. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Huge Alerts or Sideways Frequency. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Banzai International, Inc. (NASDAQ: BNZI) on Sideways Frequency' website for additional information about the relationship between Sideways Frequency and Banzai International, Inc. (NASDAQ: BNZI).
If you have questions about your account, don't hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl. #620, Sioux Falls, S.D. 57103-7078. U.S.A..